Conference Track

Resistance and Management of Treatment-Experienced Patients

Source: CCO Independent Conference Coverage of the 2009 Conference on Retroviruses and Opportunistic Infections*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Capsule Summaries

SWITCHMRK: Switching From Lopinavir/Ritonavir to Raltegravir Improved Lipid Profiles but Failed to Demonstrate Virologic Noninferiority in Virologically Suppressed Patients With Previous Antiretroviral Experience
ESPRIT: Increase in CD4+ Cell Count With Addition of IL-2 to Antiretroviral Therapy Offers No Clinical Benefit in HIV-Infected Patients With CD4+ Cell Counts ≥ 300 cells/mm³
SILCAAT: Increased CD4+ Cell Count With Addition of IL-2 to Antiretroviral Therapy Offers No Clinical Benefit to HIV-Infected Patients With CD4+ Cell Counts Between 50-299 cells/mm³
OCTANE: Rate of Virologic Failure or Death Higher With Nevirapine- vs Lopinavir/Ritonavir-Based Antiretroviral Regimens Among HIV-Infected Women With Previous Exposure to Single-Dose Nevirapine
Short-term SC Dosing of PRO 140 Anti-CCR5 Monoclonal Antibody Well Tolerated and Associated With Significant Reductions in HIV-1 RNA
BENCHMRK-1 and -2: Raltegravir Plus OBR Potent and Durable Through Week 96 in Patients With Triple Class–Resistant HIV
EASIER: Randomized Trial Confirms Efficacy and Safety of Switching From Enfuvirtide to Raltegravir in Virologically Suppressed Patients With Multidrug-Resistant HIV
STEAL: Similar Virologic Efficacy, Different Safety Profiles in Virologically Suppressed HIV-Infected Patients Who Switched to Tenofovir/Emtricitabine or Abacavir/Lamivudine
MOST: Failure of Lopinavir/Ritonavir Maintenance Monotherapy Predicted by Low Nadir CD4+ Cell Counts
Virologic Benefit of Directly Observed Therapy Not Maintained Among HIV-Infected Drug Users Following Switch to Self-Administered Therapy
Increasing Duration of Viral Suppression Associated With Decreased Risk of Virologic Failure in Patients With Antiretroviral Adherence Levels ≥ 50%
Switching to Second-line Antiretroviral Therapy Effective in Urban South African Clinic Cohort
Case Series Suggests No Benefit to Continuing Raltegravir in Patients With Virologic Failure and Presence of Raltegravir-Associated Resistance Mutations
MOTIVATE: Prevalence of Phenotypic Resistance to Maraviroc in Treatment-Experienced Patients With CCR5-Tropic Virus at Virologic Failure

Expert Analysis

Resistance and Management of Treatment-Experienced Patients

Faculty:

Eric S. Daar, MD
Joseph J. Eron, Jr., MD
Kimberly Y. Smith, MD, MPH

Learning Objectives

Upon completion of this activity, participants should be able to:

Discuss new data on the durability of response to raltegravir and strategies to manage patients with virologic failure on raltegravir-containing regimens
Describe the patterns of tropism and resistance among patients failing maraviroc in the MOTIVATE trials
Recount the key findings from studies in which patients with virologic suppression were switched to new regimens, including SWITCHMRK, EASIER, STEALTH, and MOST
Discuss the clinical endpoint data from studies in which interleukin-2 was added to antiretroviral therapy
Outline recent findings regarding the relationship among adherence to antiretroviral therapy and virologic outcomes

Abstract

Click here to view abstract

CREDIT INFORMATION

Release Date: March 25, 2009

Expiration Date: March 24, 2010

Physicians: maximum of 1.5 AMA PRA Category 1 Credits™

Registered Nurses: 1.6 Nursing contact hours

Pharmacists: 1.6 contact hours (0.16 CEUs)

Status: The activity is not currently available for credit.

Disclaimer: The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.